Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
No breakfast/beverage only, Breakfast, 10004RF · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| No breakfast/beverage only | PLACEBO_COMPARATOR | 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener |
| Breakfast | ACTIVE_COMPARATOR | 1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener |
| 10004RF | EXPERIMENTAL | 1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener |
| Name | Type | Description |
|---|---|---|
| No breakfast/beverage only | OTHER | 12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener |
| Breakfast | OTHER | 1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener |
| 10004RF | OTHER | 1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener |
Inclusion Criteria: 1. type 2 diabetes 2. between 21 and 75 years of age 3. male or a non-pregnant, non-lactating female, at least 6 weeks postpartum or postmenopausal or surgically sterile 4. BMI is \> 18.5 kg/m2 and \<35 kg/m2 5. If subject is on a chronic medication such as an anti-hypertensive,...
10004RF is an investigational nutritional product being studied for its effect on metabolic parameters in people with Type 2 Diabetes Mellitus. It is being developed by Abbott Laboratories and is currently in Phase 2 clinical development. The product is intended for use in adults aged 18 years and older.
Abbott Laboratories (NYSE: ABT) is developing 10004RF. The company is conducting clinical research to evaluate the product's effect on metabolic parameters in subjects with Type 2 Diabetes Mellitus. The product is currently in Phase 2 development and is not yet approved for commercial use.
10004RF is in Phase 2 clinical development. It is an investigational product being studied for Type 2 Diabetes Mellitus. The product has completed one Phase 2 trial and is not yet approved by regulatory authorities. It remains under clinical investigation to assess its effects on metabolic parameters.
10004RF has been studied in one completed clinical trial, NCT01324921, titled 'Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics.' This Phase 2 trial enrolled 37 participants in the United States and was placebo-controlled. The study included adults aged 18 years and older with Type 2 Diabetes Mellitus.
10004RF is a nutritional product being studied in the context of meal consumption. The clinical trial NCT01324921 evaluated the product's effect on metabolic parameters in subjects with Type 2 Diabetes Mellitus. The product is being developed by Abbott Laboratories and is currently in Phase 2 clinical development.